HFrEF Polypill
Phase 3Small molecule
HFrEF Polypill is one of 5 small molecule programs targeting Heart Failure With Reduced Ejection Fraction. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Heart Failure With Reduced Ejection Fraction
#DrugCompanyPhaseTrials
1HFrEF Polypill
WWashington University School of Medicine
Phase 3
Pharmacological Rate Control
UUniversity of British Columbia
Phase 3
Proamatine
TakedaPreclinical
Ozempic
Novo NordiskPreclinical
Lumacaftor
Vertex PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HFrEF Polypill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details